• Studies on the epidemiology of Parabacteroides merdae in humans are quite limited. However, evidence suggests it is a common inhabitant of the gut microbiota. According to Wang et al., its average abundance was 1.27% across 12 populations, ranging from 0.01% to 5.89%. In other study, Sakamoto et al. isolated P. merdae from 11.9% of fecal samples from 67 healthy Japanese adults, with higher prevalence in males. Additionally, P. merdae was detected in 10.8% of fecal samples from 37 ulcerative colitis patients, an inflammatory bowel disease.
• Factors influencing P. merdae’s distribution and abundance remain unclear, though diet, genetics, age, and medication may play a role. For instance, Dione et al. found higher levels in rural Senegalese children compared to urban French children, linked to millet consumption rich in resistant starch. Similarly, Kim et al. reported increased abundance in colorectal cancer patients versus healthy controls, correlating with animal fat and red meat intake. Understanding P. merdae’s presence and potential implications requires further research.

• The bacterium Parabacteroides merdae lives in human guts. It has unique traits in the Bacteroidetes group. P. merdae is Gram-negative; its so that cell wall has a thin peptidoglycan layer and an outer membrane. Unlike some bacteria, it can’t form spores, so harsh conditions can harm it. Also, it doesn’t move, having any flagella or pili for motion or sticking to surfaces.
• P. merdae has a rod shape, usually 0.8 to 1.6 micrometers wide and 1.2 to 12 micrometers long. What’s more, its structure includes tetramers complexes of four matching subunits with an extended caspase-like α/β/α sandwich and an unconventional C-terminal domain. These traits make P. merdae distinct and help it thrives in the human guts’ microbiome.

• Antigenic types of Parabacteroides merdae in humans require more re-search. However, a few potential methods are proposed. LPS is a pro-inflammatory molecule.
• It triggers immune system activation. Also, antibodies can recognize LPS. Thus, using Parabacteroides merdae’s LPS as an antigenic marker may be viable.

• The exact way P. merdae affects humans isn’t apparent yet. Some possible processes have been suggested, though.
• It produces fatty acids like acetate and propionate. These have anti-inflammatory effects. They also regulate the immune system’s actions. Additionally, they control genes involved in fat breakdown, blood sugar levels, and energy use.
• P. merdae may enhance gut barrier function, too. It reduces the movement of endotoxins and harmful substances into the bloodstream. This prevents activating the innate immune system and systemic inflammation.
• This microbe interacts with other gut microbes in the gut, affecting their functions. It can break down branched-chain amino acids like leucine, isole-ucine, valine – linked to insulin resistance, hardened arteries. Decreasing these amino acids protects against heart, blood vessel damage.
• P. merdae may affect how the host’s genes are expressed. It may impact epigenetic changes and hormone signaling too. So, it potentially impacts various bodily processes and disease outcomes.

In humans, the defenses against Parabacteroides merdae aren’t deeply explored. Potential mechanisms may include:

• The immune system recognizes and eliminates it by sensing lipopolysaccharide (LPS), which activates innate immunity.
• Dietary factors like resistant starch, animal fat, and red meat modulate its abundance and activity.
• Some good gut ge­rms, like Bifidobacterium and Lactobacillus, fight against P. merdae­. These helpful bacte­ria make anti-inflammatory compounds
• called short-chain fatty acids (SCFAs). They stop the­ bad bacteria from causing harm. Though small, their role is crucial for dige­stive. Defenses could vary based on lifestyle, environment, and health status. More research is needed to understand P. merdae’s interactions with humans.

• Parabacteroides merdae is a kind of bacteria from the Parabacteroides group. These bacteria make up the human gut’s core microbes. Parabacteroides merdae links to health issues like high blood pressure, polycystic ovary syndrome, and gum disease. Some signs of Parabacteroides merdae infection include:
• Tooth abscess – pus forming near the tooth or gum from a bacterial infection. Parabacteroides merdae may contribute to tooth abscesses with other oral germs.
• Periodontitis – severe gum infection harming teeth-supporting tissue and bone. Parabacteroides merdae could fuel inflammation and tissue damage in periodontitis.
• Lung abscess – a pus-filled cavity in lung tissue, often from inhaling mouth bacteria. In chronic lung disease or weakened immunity, Parabacteroides merdae might cause lung abscesses.
• Empyema – pus buildup between lungs and chest wall. With lung infection or chest injury history, Parabacteroides merdae could lead to empyema.

• There are many ways to diagnose Parabacteroides merdae infections. You can use culture, molecular, and immunological methods. Culture uses anaerobic media to grow the bacteria. It identifies P. merdae by its looks and chemicals. But it takes time, costs money, and isn’t available eve-rywhere. Molecular uses PCR to find P. merdae genes. It needs special e-quipment. It can’t tell live and dead bacteria apart. Immunological
• measures antibodies or antigens of P. merdae. It uses ELISA and other tests. But it may get mixed up with other things.

• Supporting gut wellness reduces issues with Parabacteroides merdae:
• Ensure balanced eating high in fiber, prebiotics, & probiotics nourishes good gut microbes to strengthen the gut barrier.
• Restrict broad-spectrum antibiotics, as P. merdae resists some, to avoid unsettling the gut’s microbe mix.
• Monitor symptoms linked to risks like obesity or inflammatory bowel problems and seek medical counsel promptly if needed for proper handling of P. merdae presence.

• Streamlined Genetic Manipulation of Diverse Bacteroides and Parabacteroides Isolates from the Human Gut Microbiota | mBio (asm.org)
• Parabacteroides merdae (Johnson et al.) Sakamoto and Benno – 43184 | ATCC